Accelerating Innovation in Life Sciences: The Race for Optimization

Life sciences companies are investing heavily in automation. This year, 95% of life sciences manufacturers are either using or considering smart technologies throughout their processes. With the spike in AI capabilities, almost the entire industry is prioritizing optimization to stay competitive. Those who aren’t adopting AI into their operations or the drug development cycle could quickly lose their competitive edge.

But where is this optimization happening? Let’s look at the ways the life sciences industry is prioritizing automation and optimization across supply chains, manufacturing, and talent.

Where Is the Life Sciences industry Accelerating?

Speed, agility, and regulatory alignment are key across all areas of life sciences. The movement towards optimization and the race to innovate rests primarily in these areas:

AI and automation in life sciences research
Talent and skills gaps due to AI
Global delivery models
Compliance standards
Regulatory support

But all of these areas play into each other. For example, speeding up clinical trials through automated processes means global delivery must accelerate. And in the wake of optimizing the supply chain in global delivery, compliance must keep up. That’s why companies must consider how changes in one part of the business affect the others, and they must gameplan how speed and optimization affect the full landscape.

Why Life Sciences Companies Must Optimize Operations

The rise of AI and Automation

In 2024, the global AI market in life sciences was valued at $2.28 billion. And it’s not slowing down anytime soon. AI is redefining day-to-day work in life sciences everywhere, from regulatory affairs to vaccine and drug development.

The continued introduction of new technology and the universal adoption of automated practices allows great opportunity for faster innovation—but it also reveals a widening talent gap. Life sciences companies need AI professionals in every sector. In a recent survey, almost 80% of participants point to this skills gap as a major barrier for their organization. While automation can help fill gaps in the short-term, skilled labor shortages remain a problem for leaders attempting to not only keep up with the industry but innovate as well.

Life sciences companies who invest wisely in upskilling their workforce and in acquiring skilled talent, especially at the senior level, are poised for success moving towards the future. We know this firsthand because we are actively supporting the growth of life sciences companies through talent solutions.

Drug Development Timelines

From preclinical studies and clinical trials to drug review and pharmacovigilance, AI is revolutionizing drug development in life sciences research. Typical development timelines—from testing to approval—can range anywhere from 10-30+ years depending on the type of drug and the field of development. AI has cut this timeline down drastically. Chemical discovery that once took scientists many years now takes no time at all. In fact, in the case of Insilico’s AI-generated lung fibrosis drug, it only took eighteen months. Trial phases that once took years can now only take weeks to complete.

AI is also affecting the way clinical trials are designed. Today, they focus on a data-driven approach grounded in simulations that can run safely and quickly. These simulations identify necessary mid-trial changes, recruit and match patients to relevant trials, and enhance processes surrounding trial safety monitoring and pharmacovigilance.

Global Delivery and Regulation

Regulators like the Food and Drug Administration (FDA) are encouraging the use of AI in phases like preclinical trials. Regulatory approval of folding automations into the drug development cycle both speeds up the testing and trials phase and demonstrates that compliance standards are shifting rapidly.

As clinical trials continue to accelerate, life sciences companies need to expand their supply chains to include global talent and delivery. In a post-pandemic world, global supply chain vulnerabilities are a major consideration.

Life sciences companies are rethinking their shoring models, navigating changing compliance standards, and shifting from vendor overload to vendor consolidation. Functional service providers (FSPs) also play a big role in navigating these challenges in a flexible and scalable way, bridging the gap between traditional staffing and full-service outsourcing on a global scale.

Your Partner for Optimized Solutions

From research and development (R&D) and regulatory affairs to AI integration and supply chain support, Insight Global is an FSP that delivers end-to-end life sciences solutions. We go beyond staffing to build purpose-driven teams and custom delivery models that support your company’s talent and technology needs. Smarter science starts with the right people, and the right people know how to take your business to the next level.

Ready to accelerate your innovation and lead the way in life sciences? Our experts sit at the forefront of technological innovation and talent solutions. And the pace of innovation will only continue to increase. Reach out to our experts today—we’re poised to help you grow and become a leader in the life sciences industry.